All News
ACR 2024 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Read Article
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.
Read Article
A#2531 @AlisaMueller
CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm
Are there gene depletions that affect inflamm pathways?
👉SIX1 reduces inflamm potentiation
👉NFIL3 deletion promotes inflamm, degradation
@RheumNow #ACR24 https://t.co/Nqghb5UaBR
Links:
Eric Dein ericdeinmd ( View Tweet)
Imaging in TAK Diagnosis
@KQuinnRheum @RheumNow
⭐ Take homes ⭐
👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK
👉FDG PET -focal uptake in TAK vs diffuse in GCA
👉MRI good surrogate for disease activity where PET unavailable
#ACR24 https://t.co/UWxTAZScIt
Links:
Patricia Harkins DrTrishHarkins ( View Tweet)
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition?
Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt
NO difference in relapse rate at 26, 52 wks despite addition of Anakinra
@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Comparison of infection risk across b/tsDMARDs in IA in real-world study
Treatment with
➡️Rituximab
➡️JAKi
➡️Anti-IL6
assoc with ⬆️⬆️ risk of severe infection compared to TNFi
A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs
Ab1716 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Is #IL1 inhibition for 4 months a winner in #GCA —NOPE
Anakinra daily 100mg sc 4/12
Underpowered but equal relapses and d/c #steroids not different
#relapses esp after d/c #anakinra
N=30 d/c due to #COVIDpandemic
#1699 #ACR24 @RheumNow @ACRheum https://t.co/1TgloS5x8O
Janet Pope Janetbirdope ( View Tweet)
de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX
Richard Conway RichardPAConway ( View Tweet)
#1165
📊 PBMCs of IIM patients with myocarditis(n=4) showed distinct gene expression v controls(n=4) v IIM alone(n=4)👇
💥 B-cell dysregulation may drive myocarditis in IIM
🎯Key immunological insights into🫀involvement in IIM
#ACR24 @RheumNow @JuliePaikMD @jhrheumatology https://t.co/PceZUS929S
Links:
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/EVLUyvpBfD
Links:
Janet Pope Janetbirdope ( View Tweet)
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Diagnosis and Management of Kawasaki Disease
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Dr. John Cush RheumNow ( View Tweet)
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.… https://t.co/zlJrusJDM4 https://t.co/cuumClbN6b
Dr. John Cush RheumNow ( View Tweet)
New download available!
Substitute Inflammatory Measures
https://t.co/FiZSvvl5DA https://t.co/QwVefFLcHO
Dr. John Cush RheumNow ( View Tweet)
A Keto Diet for Autoimmune Disorders?
Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis.
https://t.co/7mX6Ue4FdX https://t.co/qtOwdKfqu4
Dr. John Cush RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/2Om0IIFVnG https://t.co/W7mbdPh9ee
Dr. John Cush RheumNow ( View Tweet)
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush RheumNow ( View Tweet)
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Links:
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Mucosal Disruptions as Initiators of Rheumatoid Arthritis
The microbiome and mucosal disruptions are believed to play a role in autoimmunity, particularly rheumatoid arthritis (RA). This is linked to the "mucosal hypothesis" of RA. A recent review by Hollers, et al. discusses… https://t.co/79khnkajMy https://t.co/UvZWwJ3ERg
Dr. John Cush RheumNow ( View Tweet)
